HK Stock Market Move | OCUMENSION-B(01477) morning rose more than 7%, OT-502 new drug marketing registration application was approved for the treatment of post-operative ocular inflammation.

date
11:48 03/07/2026
avatar
GMT Eight
According to the draft, Euconavis Bio-B (01477) rose more than 7% in the morning session, with a 7.45% increase, reaching HK$5.05, with a turnover of HK$6.3473 million.
OCUMENSION-B(01477) rose more than 7% in the morning, as of the time of writing, it rose by 7.45% to HK$5.05, with a turnover of HK$6.3473 million. In terms of news, OCUMENSION-B announced that a new drug, OT-502 (DEXYCU, Visionary, Dexamethasone Suspension for Intraocular Injection), for the treatment of postoperative ocular inflammation, has recently received approval for new drug registration application from the National Medical Products Administration (NMPA) of the People's Republic of China. OT-502 (DEXYCU, Visionary, Dexamethasone Suspension for Intraocular Injection) is a single dose sustained release suspension of dexamethasone (a corticosteroid) used for the treatment of postoperative ocular inflammation. So far, OT-502 is the first and only single dose sustained release intraocular corticosteroid approved by the U.S. Food and Drug Administration for the treatment of postoperative inflammation.